Loreev XR (Lorazepam) Patent Expiration, LOE Window & CMS Spending
Loreev XR (Lorazepam) by Almatica: FDA Orange Book LOE 2034-01-08, 10 AB generics, $4.2M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Almatica |
| FDA Application & Pathway | N214826 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2034-01-08 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 10 |
| 2024 CMS Total Public Spend | $4.2M |
| 2024 Medicare Part D Spend | $2.2M |
| 2024 Medicaid Spend | $2.0M |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 56.6% 2-yr change) |